CYLD inhibits melanoma growth and progression through suppression of the jnk/ap-1 and β1-integrin signaling pathways

Journal of Investigative Dermatology

Volumn 133, Issue 1, 2013, Pages 221-229

  Ke, Hengning ^a   Augustine, Christina K ^a,b   Gandham, Vineela D ^a   Jin, Jane Y ^a   Tyler, Douglas S ^a,b   Akiyama, Steven K ^c   Hall, Russell P ^a   Zhang, Jennifer Y ^a,d  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; COLLAGEN TYPE 4; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 3; PROTEIN CYLD; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MELANOCYTE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 84872184573     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.253     Document Type: Article

References (41)

1. Alexaki VI, Javelaud D, Mauviel A (2008) JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 21:429-388
2. Alexandrescu DT, Ichim TE, Riordan NH et al. (2010) Immunotherapy for melanoma: Current status and perspectives. J Immunother 33:570-900
3. Bignell GR, Warren W, Seal S et al. (2000) Identification of the familial cylindromatosis tumour-suppressor gene. Nat Genet 25:160-55
4. Brummelkamp TR, Nijman SM, Dirac AM et al. (2003) Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NFkappaB. Nature 424:797-8011
5. Fogerty FJ, Akiyama SK, Yamada KM et al. (1990) Inhibition of binding of fibronectin to matrix assembly sites by anti-integrin (alpha 5 beta 1) antibodies. J Cell Biol 111:699-7088
6. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-77
7. Hegerfeldt Y, Tusch M, Brocker EB et al. (2002) Collective cell movement in primary melanoma explants: Plasticity of cell-cell interaction, beta1- integrin function, and migration strategies. Cancer Res 62:2125-21300
8. Hellerbrand C, Bumes E, Bataille F et al. (2007) Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28:21-77
9. Hirai Y, Kawamata Y, Takeshima N et al. (2004) Conventional and arraybased comparative genomic hybridization analyses of novel cell lines harboring HPV18 from glassy cell carcinoma of the uterine cervix. Int J Oncol 24:977-866
10. Hodgson L, Dong C (2001) [Ca2+]i as a potential downregulator of alpha2beta1-integrin-mediated A2058 tumor cell migration to type IV collagen. Am J Physiol Cell Physiol 281:C106-133
11. Huang Y, Boskovic G, Niles RM (2003) Retinoic acid-induced AP-11 transcriptional activity regulates B16 mouse melanoma growth inhibition and differentiation. J Cell Physiol 194:162-700
12. Hutti JE, Shen RR, Abbott DW et al. (2009) Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 34:461-722
13. Jenner MW, Leone PE, Walker BA et al. (2007) Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110:3291-3000
14. Jin JY, Ke H, Hall RP et al. (2011) c-Jun promotes whereas JunB inhibits epidermal neoplasia. J Invest Dermatol 131:1149-588
15. Juliano RL, Ming X, Nakagawa O et al. (2011) Integrin targeted delivery of gene therapeutics. Theranostics 1:211-99
16. Ke H, Harris R, Coloff JL et al. (2010) The c-Jun NH2-terminal kinase 2 plays a dominant role in human epidermal neoplasia. Cancer Res 70:3080-88
17. Kikuno N, Shiina H, Urakami S et al. (2008) Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Int J Cancer 123:552-600
18. Kovalenko A, Chable-Bessia C, Cantarella G et al. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424:801-55
19. Linos E, Swetter SM, Cockburn MG et al. (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666-744
20. Lopez-Bergami P, Huang C, Goydos JS et al. (2007) Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11:447-600
21. Massoumi R (2011) CYLD: A deubiquitination enzyme with multiple roles in cancer. Future Oncol 7:285-977
22. Massoumi R, Chmielarska K, Hennecke K et al. (2006) Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125:665-777
23. Massoumi R, Kuphal S, Hellerbrand C et al. (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 206:221-322
24. Miliani de Marval P, Lutfeali S, Jin JY et al. (2011) CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. Cancer Prev Res (Phila) 4:851-99
25. Mould AP, Garratt AN, Askari JA et al. (1995) Identification of a novel antiintegrin monoclonal antibody that recognises a ligand-induced binding site epitope on the beta 1 subunit. FEBS Lett 363:118-222
26. Na SY, Choi JE, Kim HJ et al. (1999) Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation. J Biol Chem 274:28491-66
27. Nakahara H, Nomizu M, Akiyama SK et al. (1996) A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. J Biol Chem 271:27221-44
28. Pinon P, Wehrle-Haller B (2010) Integrins: Versatile receptors controlling melanocyte adhesion, migration and proliferation. Pigment Cell Melanoma Res 24:282-944
29. Regamey A, Hohl D, Liu JW et al. (2003) The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med 198:1959-644
30. Reiley W, Zhang M, Sun SC (2004) Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 279:55161-77
31. Reiley WW, Jin W, Lee AJ et al. (2007) Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med 204:1475-855
32. Reiley WW, Zhang M, JinWet al. (2006) Regulation of T cell development by the deubiquitinating enzyme CYLD. Nat Immunol 7:411-77
33. Stegmeier F, Sowa ME, Nalepa G et al. (2007) The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci USA 104: 8869-744
34. Strobel P, Zettl A, Ren Z et al. (2002) Spiradenocylindroma of the kidney: Clinical and genetic findings suggesting a role of somatic mutation of the CYLD1 gene in the oncogenesis of an unusual renal neoplasm. Am J Surg Pathol 26:119-244
35. Trompouki E, Hatzivassiliou E, Tsichritzis T et al. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424:793-66
36. Ueda Y, Richmond A (2006) NF-kappaB activation in melanoma. Pigment Cell Res 19:112-244
37. Wang L, Baiocchi RA, Pal S et al. (2005) The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol 25:7953-655
38. Wilkinson KD (1997) Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 11:1245-566
39. Yang S, McNulty S, Meyskens Jr FL (2004) During human melanoma progression AP-1 binding pairs are altered with loss of c-Jun in vitro. Pigment Cell Res 17:74-833
40. Zhang JY, Adams AE, Ridky TW et al. (2007) Tumor necrosis factor receptor 1//c-Jun-NH2-kinase signaling promotes human neoplasia. Cancer Res 67:3827-344
41. Ziober BL, Chen YQ, Ramos DM et al. (1999) Expression of the alpha7beta11 laminin receptor suppresses melanoma growth and metastatic potential. Cell Growth Differ 10:479-900